Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ACTUATE THERAPEUTICS, INC. (ACTU)

Actuate Therapeutics receives Nasdaq notice over $50 million market value requirement

Negative Impact 5 of 5 legal/regulatory Written later

Actuate Therapeutics received a Nasdaq notice that its Market Value of Listed Securities fell below the $50 million minimum for continued listing on the Nasdaq Global Market from June 1, 2026 to July 14, 2026. The common stock continues to trade under the symbol ACTU, and the company has until January 11, 2027 to regain compliance, which could lead to delisting proceedings if it does not.

Key points

  • Nasdaq notice dated July 15, 2026 cites a market value of listed securities below the $50 million minimum for the period June 1, 2026 to July 14, 2026.
  • The common stock continues to trade on the Nasdaq Global Market under ACTU, as the notice has no immediate effect on listing.
  • Compliance Date is January 11, 2027; regaining compliance requires closing at $50 million or more for at least ten consecutive business days.
  • If compliance is not regained, Nasdaq will issue a delisting notice, which the company may appeal, or the company may consider transfer to the Nasdaq Capital Market.

The filing

CompanyACTUATE THERAPEUTICS, INC. (ACTU)
Form8-K, current report
Filed with the SECJul 17, 2026, 4:30 PM ET
Accession number0001683168-26-005616

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.